Sentences with phrase «risk of estrogen»

These get in the body and mimic the effects of estrogen causing things like weight gain, mood disorders, and increased risk of estrogen - linked cancers.

These associations were primarily limited to hormone receptor — positive tumors as migraine was associated with a 0.65-fold (95 % CI, 0.51 - 0.83) reduced risk of estrogen receptor — positive (ER +) / progesterone receptor — positive (PR +) ductal carcinoma.

If you want to stay on the pill you can minimise the risk of estrogen dominance by eating a clean diet, reducing stress and getting lost of minerals especially magnesium.

Additionally, if your hormone replacement therapy does not also include progesterone, you're running the risk of estrogen dominance, which many women already suffer.

In a 2009 study in the journal, Breast Cancer Research and Treatment, researchers found that dietary acrylamide intake was associated with increased risk of estrogen receptor - positive breast cancer, but the same was not found with estrogen receptor - negative breast cancer.

«We found a strong reduction in the risk of estrogen - receptor - negative [ER --RSB- breast cancer in particular, which is exciting because that type of tumor, while rarer than estrogen - receptor - positive [ER +] tumors, tends to be aggressive.»

Indoles convert excess estrogen into a safer form, which significantly reduces the risk of estrogen - linked cancers, such as breast cancer and prostate cancer.

Plastic bottles contain xenoestrogens, which increase the risk of estrogen - related cancers and contribute to many health issues.

High total and saturated fat intake were associated with greater risk of estrogen receptor - and progesterone receptor - positive (ER+PR +) breast cancer (BC), and human epidermal growth factor 2 receptor - negative (HER2 --RRB- disease, according to a new study published April 9 in the Journal of the National Cancer Institute.

Breastfeeding reduces risk of both estrogen - negative and estrogen - positive breast cancers.

Breastfeeding may be especially helpful at reducing risk of estrogen receptor negative, including triple negative, breast cancers.

Not exact matches

«Women who are high risk for blood clots include those using an estrogen - containing birth control who smoke cigarettes over the age of 35.»

Yes, there are many dietary and environmental factors that affect breast cancer risk, most of which are presumed to act via increasing or decreasing the levels of estrogens or estrogen - like substances to which women are chronically exposed.

Finally, arugula, technically considered a cruciferous vegetable (like broccoli and cabbage), is in a group of foods that contains di - indoly methane, or DIM which helps to promote healthy estrogen balance and reduces the risk of some cancers.

For kids, many parents also try to avoid products with bisphenol - A (BPA) because of concerns about its potential to mimic estrogen, lead to reproductive problems, increase the risk of cancer and interfere with brain development and fat metabolism.

Because a female's body needs estrogen to absorb calcium for strong bones, not enough estrogen can cause bones to lose thickness and strength, resulting in a greater risk of stress fractures and osteoporosis.

Researchers have found that breastfeeding also lowers the risk of developing estrogen receptor - negative (including triple negative) breast cancers.

Estrogen injections aren't used today, however, due to a possible risk of potentially dangerous blood clots.

Bisphenol A mimics the estrogen hormone and at high enough levels could increase the risk of cancer, birth defects or reproductive problems.

It's usually suggested that you wait four to six weeks after delivery to start using any birth control methods that contain estrogen (like some birth control pills, the ring, and the patch) because estrogen can increase the risk of blood clots during the early postpartum period.

Low estrogen levels are clearly linked to a reduced risk of breast, uterine, and ovarian cancer.

(Progesterone is added to hormone therapy to protect the uterus lining from a risk of cancer seen with estrogen alone.)

Looking at the data in this way showed that absolute risk for health problems for women on a combined formulation of estrogen plus synthetic progesterone was lowest for the youngest women, who are most likely to experience menopausal symptoms.

Recently, Manson and colleagues published a long - term study of the risk of death in women in the two WHI hormone therapy trials — combined therapy and estrogen alone — from the time of trial enrollment in the mid-1990s until the end of 2014.

For example, levels of estrogen and androgen receptors were upregulated in female - associated placentas while inflammatory markers associated with increased risk of behavioral disorders were upregulated in placentas from both sexes.

Estrogens have been reported to exert protective vascular effects in animal and observational but randomized clinical trials did not report such effects in older women, even suggesting the possibility of an increased CVD risk in this setting, especially with combined estrogen plus progestin therapy.

In 2001 the trend reversed: Breast cancer rates initially dipped gradually, but dropped sharply in mid-2002, when many women in the U.S. stopped hormone replacement therapy after the Women's Health Initiative, a large clinical trial involving estrogen - progestin therapy, was stopped after it was determined that the risks — most notably the increased likelihood of developing breast cancer — outweighed the benefits.

The U.S. study testing the long - term benefits and risks of hormone replacement therapy (HRT) was halted after an interim analysis found that the drugs — a combination of estrogen and progestin — increased the risk of breast cancer, stroke, and heart disease, and that those risks outweighed reduced risks of colorectal cancer and bone fractures (ScienceNOW, 9 July).

The risk of having a heart attack was somewhat — but not significantly — higher in women using oral conjugated equine estrogens than in those using oral estradiol.

Although it still can not be cured, or even treated very well, several recent studies hint that some treatments — from estrogen to vitamin E to anti-inflammatory drugs — can reduce either the risk of developing the disorder or its symptoms.

But in an observational study of comparative safety, use of estradiol was associated with less risk of developing blood clots in leg veins (deep vein thrombosis) and clots in the lungs (pulmonary emboli) than was use of conjugated equine estrogens.

Last summer, a panel of 38 researchers headed by vom Saal published a report in Reproductive Toxicology warning that BPA (much like the synthetic estrogen diethylstilbestrol, or DES) is a potential chemical time bomb that may lead to multiple problems, including a higher risk of cancer, especially if exposure occurs in the womb or an infant's early life and on an unrelenting daily basis.

Women who have high levels of both testosterone and estrogen in midlife may face a greater risk of developing benign tumors on the uterus called uterine fibroids than women with low levels of the hormones, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

The sensor sends an electronic signal is the presence of estrogen and, with further development, could test estrogen levels in bodily fluids or test waterways for estrogen contamination that might pose a risk to humans and the environment.

Women who had high levels of testosterone and estrogen faced an even greater risk.

estrogen administration to post-menopausal female mice led the Geneva scientists to make a first observation: they identified an increased tolerance to glucose, which is correlated to a lower risk of diabetes.

Thus, as estrogen levels fall during menopause, the risks of increased blood pressure and development of cardiovascular disease increases.

Estrogen therapy reduced some of the risk in women who had undergone the procedure.

Estrogen patches and progestin - only injections were both associated with slightly increased risks of thromboembolism.

The drop in hormone use dates back to July 2002, when the Women's Health Initiative, a 15 - year study tracking the health of more than 160,000 women, abruptly ended its long - term study of estrogen - progestin hormone replacement therapy because women taking the drugs faced an elevated risk of invasive breast cancer and heart disease.

Some examples of the scholars» projects are: effects of estrogen on cardiac fibrosis after myocardial infarction, depression and the growth - hormone axis, substance abuse, stress and nicotine, cardiovascular risk in spinal cord injury, and pharmacogenomics and the treatment of breast cancer in elderly women.

Because hearing loss becomes more common after menopause, the point in a woman's life when estrogen and progestogen levels fall off, it has long been assumed that HT would help reduce the risk of hearing loss.

Heavy drinkers who consume more than eight drinks a day have a 63 percent increased risk of female breast cancer because alcohol increases levels of the female sex hormone estrogen.

Hormonal therapy for patients with estrogen - or progesterone - positive breast cancers can reduce the risk of cancer recurrence by as much as 50 percent.

A 2008 study at Sweden's Lund University demonstrated that drinking coffee lowers the risk of breast cancer, at least for women who have a relatively common variant of the gene CYP1A2, which helps to metabolize both estrogen and coffee.

In cases of prostate cancer and estrogen - receptor positive breast cancer, the DKFZ epidemiologists found no links between immunoCRIT and cancer risk.

Women with very high immunoCRIT even have a triple increase in their risk of developing estrogen - receptor negative breast cancer.

Prior to the WHI, the accepted view among physicians was that estrogen therapy reduced a woman's risk of developing cognitive impairment.

In June researchers from the Women's Health Initiative Memory Study added a dismal confirmation: estrogen - only replacement therapy in postmenopausal women who've had a hysterectomy not only fails to prevent memory loss but may also increase the risk of dementia.

Over the last two years, the Women's Health Initiative, a series of long - term studies funded by the National Institutes of Health, revealed that taking an estrogen - progestin combination slightly increases the risk of stroke and blood clots and may also increase the risk of heart disease, breast cancer, and dementia.